About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Boston | 8,503 Studies Near You | Clareo Health

Clinical Trials LocationsBoston

Clinical Trials in Boston

Discover 8,503 clinical trials near Boston, Massachusetts. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 2181-2200 of 8,503 trials

Not Yet RecruitingNA< 1 mile

Early Intervention

NCT05326165

This research study is a Pilot Study examining the use of a compression sleeve with embedded sensor to prevent lymphedema.

Breast CancerBreast Cancer Treatment Related Lymphedema

Massachusetts General Hospital40 participantsStarted May 2026

Boston, Massachusetts, United States

TERMINATEDPhase 2< 1 mile

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

NCT04830124

This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma

Cutaneous MelanomaMucosal Melanoma

Mural Oncology, Inc173 participantsStarted Sep 2021

La Jolla, California, United States • Los Angeles, California, United States • Jacksonville, Florida, United States +38 more locations

Find Trials by Condition in Boston

Breast Cancerin Boston Lung Cancerin Boston Prostate Cancerin Boston Colorectal Cancerin Boston Melanomain Boston Leukemiain Boston Lymphomain Boston Pancreatic Cancerin Boston Ovarian Cancerin Boston Brain Cancerin Boston Diabetesin Boston

Data from ClinicalTrials.govTerms

Enrolling By InvitationNA< 1 mile

Promoting Shared Decision Making for Severe Aortic Stenosis

NCT06171737

The goal of this study is to increase shared decision making for patients considering treatment for severe aortic stenosis. The main questions it aims to answer are: * Do patient decision aids and clinician skills training course improve the quality of decisions, and do they work well for different patient populations? * Are heart clinics able to reach the majority of patients with decision aids before their specialist visit and do the majority of clinicians complete the training course? All participating sites will start in the usual care group and then will be randomly assigned a time to switch to the intervention group. Participants will complete surveys before and after their specialist visit. Researchers will compare data from patients seen during usual care with data from those seen after the interventions are implemented to see if there are improvements in the quality of decisions.

Aortic Stenosis

Massachusetts General Hospital1,300 participantsStarted Mar 2024

San Francisco, California, United States • Aurora, Colorado, United States • Atlanta, Georgia, United States +5 more locations

TERMINATEDPhase 1/2< 1 mile

TAC T-cells for the Treatment of HER2-positive Solid Tumors

NCT04727151

TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2). TAC directs T-cells to the targeted antigen (HER2), and once engaged with the target, activates them via the endogenous T cell receptor. This is an open-label, multicenter Phase 1/2 study that aims to establish safety, maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-HER2 as a monotherapy, and in combination with pembrolizumab, in subjects with HER2 positive gastric and gastroesophageal adenocarcinoma.

HER2 Positive Gastric CancerMetastatic HER2 Positive Gastroesophageal Junction Cancer

Triumvira Immunologics, Inc.28 participantsStarted Apr 2021

Chicago, Illinois, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +8 more locations

RECRUITINGNA< 1 mile

TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)

NCT06137807

The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The TricValve® Transcatheter Bicaval Valves are pre-mounted into the TricValve® Delivery System which is used for percutaneous access and delivery of the TricValve® Transcatheter Bicaval Valve in the vena cava. The system is a single use, sterile device compatible with all the valve sizes. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. The device is made of bovine pericardium leaflets sutured on a nitinol self-expanding stent system.

Tricuspid RegurgitationTricuspid Valve Disease

P+F Products + Features USA Inc.50 participantsStarted Jul 2024

Phoenix, Arizona, United States • Tucson, Arizona, United States • San Diego, California, United States +33 more locations

RECRUITINGNA< 1 mile

JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization

NCT05064540

Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).

AAAAAA - Abdominal Aortic Aneurysm

Endologix450 participantsStarted Sep 2021

Huntsville, Alabama, United States • Tucson, Arizona, United States • Fayetteville, Arkansas, United States +26 more locations

RECRUITINGPhase 1< 1 mile

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

NCT02074839

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four cohorts of patients will receive AG-120 to further evaluate the safety, tolerability, and clinical activity of the recommended Phase II dose. Additionally, the study includes a substudy evaluating the safety and tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of AG-120 in subjects with relapsed or refractory myelodysplastic syndrome with an IDH1 mutation. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.

Relapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AMLOther IDH1-mutated Positive Hematologic Malignancies+1 more

Institut de Recherches Internationales Servier291 participantsStarted Mar 2014

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Duarte, California, United States +27 more locations

COMPLETEDPhase 3< 1 mile

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

NCT03859700

Open-label, follow-up study for subjects who completed the EPITOPE study.

DBV Technologies304 participantsStarted Dec 2018

Tucson, Arizona, United States • Little Rock, Arkansas, United States • Los Angeles, California, United States +23 more locations

COMPLETED39 miles

Speech, Linguistic and Acoustic Markers in Parkinson's Disease

NCT04273672

The Investigators aim to identify speech and language markers that provide information on cognitive function and predict cognitive decline in Parkinson's disease. The Investigators will administer speech tasks and cognitive assessments to participants with Parkinson's disease and healthy controls. The Investigators will also explore the associations between genetic factors and speech and cognitive status in Parkinson's disease.

Parkinson DiseaseCognitive Impairment, MildSpeech

University of Massachusetts, Worcester58 participantsStarted Jan 2020

Worcester, Massachusetts, United States

RECRUITINGNA41 miles

Prepping for The Talk: Helping Trusted Adults and Youth Talk About Sexual Health

NCT07011563

The goal of this study is to help young people talk to trusted adults (including their parents, but also other adults) about sexual health more openly and honestly- including how to prevent sexually transmitted diseases like HIV - while also respecting a young person's right to privacy. If youth don't have a parent they can talk to about sexual health, we want to help them find a trusted adult to talk to. We also want to help youth take control of their own health by learning about different ways to protect their health.

HIV PreventionSexual Health

Rhode Island Hospital40 participantsStarted May 2025

Providence, Rhode Island, United States

Active Not RecruitingPhase 349 miles

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05599191

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

CoughRefractory Chronic Cough

Bellus Health Inc. - a GSK company825 participantsStarted Oct 2022

Litchfield Park, Arizona, United States • Scottsdale, Arizona, United States • Encinitas, California, United States +188 more locations

COMPLETEDPhase 2146 miles

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

NCT01946477

This trial will evaluate the efficacy and safety of combination of pomalidomide (POM) and low-dose dexamethasone (LD-Dex) (Cohort A) or the combination of pomalidomide (POM) , daratumumab (DARA) and low-dose dexamethasone (LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line treatment of lenalidomide-based therapy. This trial will test the hypothesis for Cohort A that the proportion of patients will have an Overall Response Rate (ORR) of \> 30 % to reveal that Pomalidomide is efficacious in pretreated patients who are refractory to lenalidomide. This trial will test the hypothesis for Cohort B that the proportion of patients will have an Overall Response Rate (ORR) of \> 70 % to reveal that POM+DARA+LD-Dex is efficacious in pretreated patients who are refractory to lenalidomide. This trial will test the hypothesis for Cohort C that the proportion of patients will have an Overall Response Rate (ORR) of \>60% to reveal that POM+DARA+LD-Dex is efficacious in pretreated patients who are refractory to lenalidomide. This treatment will be in only Japanese patients.

Multiple Myeloma

Celgene186 participantsStarted May 2014

Tucson, Arizona, United States • Greenbrae, California, United States • Los Angeles, California, United States +46 more locations

COMPLETEDPhase 3176 miles

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

NCT03938792

Treatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage and/or a major contribution to patient care in comparison to current methods of treatment for hemophilia A or B because it works differently than factor replacement products and will work in the presence of inhibitors. The potential for once weekly (QW) subcutaneous (SC) administration provides for treatment options in the absence of reliable vascular access, increased convenience and may enable better compliance. Combined, these qualities should result in a reduction of bleeding episodes.

Hemophilia AHemophilia B

Pfizer189 participantsStarted Mar 2020

Tampa, Florida, United States • Iowa City, Iowa, United States • New Hyde Park, New York, United States +59 more locations

RECRUITINGPhase 1179 miles

ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies

NCT04412616

This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Malignancies who are not able to have current standard anti-tumor therapies. The purpose of this study is to determine the maximum tolerated dose (MTD) , to characterise the safety, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of ZZ06 as a single agent in adult participants with advanced solid tumors.

Advanced EGFR Positive Solid Tumor

Changchun Intellicrown Pharmaceutical Co. LTD60 participantsStarted Sep 2020

Los Angeles, California, United States • Fairway, Kansas, United States • The Bronx, New York, United States +2 more locations

RECRUITINGPhase 1190 miles

Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

NCT06963281

The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.285 participantsStarted Apr 2025

Pheonix, Arizona, United States • Jacksonville, Florida, United States • Rochester, Minnesota, United States +6 more locations

COMPLETEDPhase 3324 miles

D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)

NCT04411199

Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to Assess Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SoC), Compared to a SoC Treated Control Arm, in Prevention of Post Abdominal Surgery Incisional Infection.

Surgical Site InfectionColon SurgeryAbdominal Surgery+1 more

PolyPid Ltd.800 participantsStarted Dec 2020

Augusta, Georgia, United States • New Orleans, Louisiana, United States • St Louis, Missouri, United States +55 more locations

TERMINATED647 miles

Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3

NCT03278873

This is a longer-term follow-up study of patients with achromatopsia associated with defects in CNGA3 who participated in a clinical trial in which they received AAV-CNGA3 retinal gene therapy, or of patients with achromatopsia associated with defects in CNGB3 who participated in a clinical trial in which they received AAV-CNGB3 retinal gene therapy.

MeiraGTx UK II Ltd34 participantsStarted Jun 2017

Ann Arbor, Michigan, United States • London, United Kingdom

COMPLETEDPhase 1/2806 miles

A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

NCT04971733

The primary objective of the study is to assess the safety and tolerability of intravenous (IV) infusions of E2814 in participants with dominantly inherited Alzheimer's disease (DIAD), and to evaluate target engagement (TE) of E2814 on microtubule binding region (MTBR)-tau species in cerebrospinal fluid (CSF) in participants with DIAD.

Alzheimer Disease

Eisai Inc.8 participantsStarted Jun 2021

La Jolla, California, United States • Indianapolis, Indiana, United States • London, United Kingdom

Active Not RecruitingNA872 miles

ProVIDE II Bridging Study

NCT06236802

The purpose of the ProVIDE II Bridging Study is to evaluate the performance of the Generation II delivery system when deploying the ProVee expander in subjects with symptomatic urinary obstruction secondary to BPH.

BPH With Symptomatic Lower Urinary Tract Symptoms

ProVerum Medical40 participantsStarted Mar 2024

Tampa, Florida, United States • Winter Garden, Florida, United States • Lake Barrington, Illinois, United States +5 more locations

Not Yet RecruitingNA2178 miles

A Study Evaluating the Safety and Efficacy of MINIject S+ in Subjects With Open Angle Glaucoma

NCT07009236

This is a prospective, multi-center, international, cohort expansion study. Part 1 will be conducted in subjects with open angle glaucoma to identify the best insertion tool for MINIject S+. In Part 1, three different investigational insertion tools will be used to place MINIject implants in this first-in man study. Each arm represents a different version of the insertion tool. Subject and independent central reader will be blinded to the insertion tool used to implant MINIject S+. Part 2 will be an expansion phase where the selected insertion tool will be assessed in a larger population of subjects with open angle glaucoma and operable cataracts undergoing combined glaucoma and cataract surgery (with IOL implantation).

iSTAR Medical30 participantsStarted Jul 2025

Santa Rosa de Copán, Honduras • Colchester, United Kingdom • London, United Kingdom

PreviousPage 110 of 426Next

Heart Diseasein Boston